Gene Activity List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Gene Compound Experiment Study Pathway Assay Report Bug Request Feature
Gene Activity List
You are on Page 103 of 1714:
93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113
Gene Compound Assay Inh Ic50 Ki View
sodium channel, voltage-gated, type II, alpha 2 MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 1 MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 2 MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
amiloride-sensitive cation channel 5, intestinal MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type VIII, alpha polypeptide MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type 10, alpha polypeptide MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha polypeptide MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha polypeptide MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1E subunit DOXORUBICIN Calcium Channel Type L, Dihydropyridine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, N type, alpha 1B subunit DOXORUBICIN Calcium Channel Type L, Dihydropyridine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha2/delta subunit 1 DOXORUBICIN Calcium Channel Type L, Dihydropyridine 33% NoneNone NoneNone View
platelet derived growth factor receptor, alpha polypeptide 3-METHYLCHOLANTHRENE Platelet-Derived Growth Factor (PDGF) 33% NoneNone NoneNone View
platelet-derived growth factor receptor, alpha polypeptide 3-METHYLCHOLANTHRENE Platelet-Derived Growth Factor (PDGF) 33% NoneNone NoneNone View
platelet derived growth factor receptor, beta polypeptide 3-METHYLCHOLANTHRENE Platelet-Derived Growth Factor (PDGF) 33% NoneNone NoneNone View
platelet-derived growth factor receptor, beta polypeptide 3-METHYLCHOLANTHRENE Platelet-Derived Growth Factor (PDGF) 33% NoneNone NoneNone View
cholinergic receptor, muscarinic 3 DOXORUBICIN Muscarinic M3 33% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type III, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type II, alpha 2 TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel associated protein 1 TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel associated protein 2 TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
amiloride-sensitive cation channel 5, intestinal TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta TACROLIMUS Sodium Channel, Site 2 33% NoneNone NoneNone View
mast cell protease 9 4-AMINO-1,8-NAPHTHALIMIDE Protease, Cathepsin G 33% NoneNone NoneNone View
adenosine A2a receptor 4-AMINO-1,8-NAPHTHALIMIDE Adenosine A2A 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 8 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 7 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 6 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 5 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 4 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 3 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 2 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 1 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 4 subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 3 subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 2 subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1S subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha 1F subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1D subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1C subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 1 subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1E subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, N type, alpha 1B subunit VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha2/delta subunit 1 VECURONIUM BROMIDE Calcium Channel Type L, Benzothiazepine 33% NoneNone NoneNone View
Cytochrom P450-2C19 monooxygenase FLUOROURACIL CYP450-2C19 Inhibition 33% NoneNone NoneNone View
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) METYRAPONE CYP450-2C9 Inhibition 33% NoneNone NoneNone View
cytochrome P450, family 2, subfamily C, polypeptide 9 METYRAPONE CYP450-2C9 Inhibition 33% NoneNone NoneNone View
FMS-like tyrosine kinase 1 S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE Vascular Endothelinal Growth Factor (VEGF) 33% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 8 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 7 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 6 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 5 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 4 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 3 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 2 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, gamma subunit 1 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 4 subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 3 subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 2 subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1S subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha 1F subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1D subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1C subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, beta 1 subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, L type, alpha 1E subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, N type, alpha 1B subunit LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
calcium channel, voltage-dependent, alpha2/delta subunit 1 LOVASTATIN Calcium Channel Type L, Dihydropyridine 32% NoneNone NoneNone View
adenosine A2a receptor TRETINOIN Adenosine A2A 32% NoneNone NoneNone View
neuropeptide Y receptor Y1 CHLORPROMAZINE Neuropeptide Y1 32% NoneNone NoneNone View
mitogen activated protein kinase 1 GOLD SODIUM THIOMALATE Protein Serine/Threonine Kinase, ERK2 32% NoneNone NoneNone View
mitogen-activated protein kinase 1 GOLD SODIUM THIOMALATE Protein Serine/Threonine Kinase, ERK2 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 SULFABENZAMIDE Cyclooxygenase COX-2 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) SULFABENZAMIDE Cyclooxygenase COX-2 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 SULFANILAMIDE Cyclooxygenase COX-2 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) SULFANILAMIDE Cyclooxygenase COX-2 32% NoneNone NoneNone View
mitogen activated protein kinase 1 TROPICAMIDE Protein Serine/Threonine Kinase, ERK2 32% NoneNone NoneNone View
mitogen-activated protein kinase 1 TROPICAMIDE Protein Serine/Threonine Kinase, ERK2 32% NoneNone NoneNone View
leukotriene C4 synthase CIMETIDINE Leukotriene C4 Synthetase 32% NoneNone NoneNone View
leukotriene C4 synthase CIMETIDINE Leukotriene C4 Synthetase 32% NoneNone NoneNone View
3-hydroxy-3-methylglutaryl-Coenzyme A reductase BETAMETHASONE PHOSPHATE HMG-CoA Reductase 32% NoneNone NoneNone View
3-hydroxy-3-methylglutaryl-Coenzyme A reductase BETAMETHASONE PHOSPHATE HMG-CoA Reductase 32% NoneNone NoneNone View
interleukin 8 receptor, beta BETAMETHASONE PHOSPHATE Chemokine CXCR2 (IL-8B) 32% NoneNone NoneNone View
5-hydroxytryptamine (serotonin) receptor 5B TAMOXIFEN Serotonin 5-HT4 32% NoneNone NoneNone View
5-hydroxytryptamine (serotonin) receptor 4 TAMOXIFEN Serotonin 5-HT4 32% NoneNone NoneNone View
Cytochrom P450-2D6 monooxygenase CLOFIBRATE CYP450-2D6 Inhibition 32% NoneNone NoneNone View
mu-opioid receptor MOR NIFEDIPINE Opiate mu 32% NoneNone NoneNone View
natriuretic peptide receptor 2 CILOSTAMIDE Atrial Natriuretic Factor (ANF) 32% NoneNone NoneNone View
guanylate cyclase A/atrial natriuretic peptide receptor (Non-specific probe) CILOSTAMIDE Atrial Natriuretic Factor (ANF) 32% NoneNone NoneNone View
natriuretic peptide receptor 3 CILOSTAMIDE Atrial Natriuretic Factor (ANF) 32% NoneNone NoneNone View
Protein-tyrosine kinase, Fyn CILOSTAMIDE Protein Tyrosine Kinase, Fyn 32% NoneNone NoneNone View
opioid receptor, kappa 1 DICYCLOMINE Opiate kappa 32% NoneNone NoneNone View
androgen receptor DIFLORASONE DIACETATE Testosterone 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) DIFLUNISAL Cyclooxygenase COX-2 32% NoneNone NoneNone View
prostaglandin-endoperoxide synthase 2 DIFLUNISAL Cyclooxygenase COX-2 32% NoneNone NoneNone View
cholinergic receptor, muscarinic 4 CISAPRIDE Muscarinic M4 32% NoneNone NoneNone View
Cytochrom P450-1A2 monooxygenase ISOEUGENOL CYP450-1A2 Inhibition 32% NoneNone NoneNone View
mitogen activated protein kinase 14 CITRININ Protein Serine/Threonine Kinase, p38alpha 32% NoneNone NoneNone View
mitogen-activated protein kinase 14 CITRININ Protein Serine/Threonine Kinase, p38alpha 32% NoneNone NoneNone View
adrenergic receptor, beta 2 TETRACAINE Adrenergic beta2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta CLENBUTEROL Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 1 CLENBUTEROL Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 2 CLENBUTEROL Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 gamma MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 beta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, gamma MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, delta MONTELUKAST Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 1 HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel associated protein 2 HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, alpha HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
amiloride-sensitive cation channel 5, intestinal HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type III, beta HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type VIII, alpha polypeptide HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type I, beta HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type 10, alpha polypeptide HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha polypeptide HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha polypeptide HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha HYDROXYPROGESTERONE Sodium Channel, Site 2 32% NoneNone NoneNone View
dopamine receptor D3 VINORELBINE Dopamine D3 31.5% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, alpha 2 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, alpha 1 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, delta CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, gamma 1 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, pi CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
AT hook, DNA binding motif, containing 1 (DBSS) CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, theta CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid A receptor, gamma 2 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 CICLOPIROX GABAA, Agonist Site 31% NoneNone NoneNone View
adrenergic receptor, beta 1 HALOPROGIN Adrenergic beta1 31% NoneNone NoneNone View
adrenergic, beta-1-, receptor HALOPROGIN Adrenergic beta1 31% NoneNone NoneNone View
histamine receptor H 1 SODIUM NITROPRUSSIDE Histamine H1, Central 31% NoneNone NoneNone View
glycine receptor, alpha 3 ALOSETRON Glycine, Strychnine-Sensitive 31% NoneNone NoneNone View
glycine receptor, alpha 1 subunit ALOSETRON Glycine, Strychnine-Sensitive 31% NoneNone NoneNone View
glycine receptor, beta subunit ALOSETRON Glycine, Strychnine-Sensitive 31% NoneNone NoneNone View
glycine receptor, alpha 2 subunit ALOSETRON Glycine, Strychnine-Sensitive 31% NoneNone NoneNone View
Cytochrom P450-2C19 monooxygenase TROGLITAZONE CYP450-2C19 Inhibition 31% NoneNone NoneNone View
adrenergic receptor, alpha 2a S-(-)-PROPRANOLOL Adrenergic alpha2A 31% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage gated, type VIII, alpha GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type III, alpha GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type II, alpha 2 GADOPENTETATE DIMEGLUMINE Sodium Channel, Site 2 31% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha polypeptide ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha polypeptide ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type II, beta ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 gamma ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 beta ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type XI, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, gamma ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, delta ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, nonvoltage-gated 1 alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type X, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IX, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage gated, type VIII, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type VII, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, beta ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View
sodium channel, voltage-gated, type IV, alpha ETHYNODIOL DIACETATE Sodium Channel, Site 2 33% NoneNone NoneNone View